Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

CEO

ISIN

US50015M1099

Listings

0 Comments

Share your thoughts

FAQ

What is Kodiak Sciences stock price today?▼

The current price of KOD.BOATS is $42.53 USD — it has increased by +8.74% in the past 24 hours. Watch Kodiak Sciences stock price performance more closely on the chart.

What is Kodiak Sciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Kodiak Sciences stocks are traded under the ticker KOD.BOATS.

What is Kodiak Sciences market cap?▼

Today Kodiak Sciences has the market capitalization of 2.26B

When is the next Kodiak Sciences earnings date?▼

Kodiak Sciences is going to release the next earnings report on May 18, 2026.

What is Kodiak Sciences revenue for the last year?▼

Kodiak Sciences revenue for the last year amounts to 0 USD.

What is Kodiak Sciences net income for the last year?▼

KOD.BOATS net income for the last year is -352.41M USD.

When did Kodiak Sciences complete a stock split?▼

Kodiak Sciences has not had any recent stock splits.